The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Buyout candidate in a major way. Why? NHL drug showed 60% effectiveness in PII trial - yes it was small but that is so statistically significant it is unlikely to go away completely. Assuming 8,000 new potential patients per year we have a drug that will bring in 500M at its peak, maybe more (depends on additional applications). Soooo... why a buyout? The cost of bringing a drug to market is approx 1.2B. They don't have that kind of $. More importantly, given the cost of getting a FDA approved manufacturing facility up and running is also a B. Should the get approval and not at least partner it they will be a victim of their own success. They (probably) know this. They need a company with deep pockets to fund their clinical trial for NHL as well as the rest of their (for their size) respectable pipeline. Looking at past deals for similar companies in this situation I would estimate the buyout at 2-3B. The only real questions are when and who.